Sinovac Biotech (Sinovac) has received a revised production license from State Food and Drug Administration (SFDA) for Panflu.1, the company’s H1N1 vaccine. Reportedly, with the revised license, the
Abbott and BG Medicine have entered into a development and commercialisation agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression
Abbott Laboratories (Abbott) has received a warning from the US regulators as it fails to follow good manufacturing practices (GMPs) standards at its Des Plaines facility, reported Daily
Broncus Technologies (Broncus) has reported early results of a double-blinded, randomised, sham-controlled EASE (Exhale Airway Stents for Emphysema) trial, for patients with emphysema/COPD. Airway Bypass is a minimally-invasive
Novavax has completed the enrollment in the first stage of a two-stage clinical study of its novel 2009 H1N1 virus-like-particle (VLP) pandemic influenza unadjuvanted vaccine in the country
PanGenex has entered into a strategic partnership with BulovaTech Labs (LABS), a wholly-owned subsidiary of Bulova Technologies Group. The new partnership supports the joint development and commercialisation of
GlaxoSmithKline and GEA have formed a consortium to improve continuous processing and pharma manufacturing efficiency in the UK. The step was taken in response to the competition from
Eisai has launched Lusedra (fospropofol disodium) injection CIV for use by persons trained in the administration of general anesthesia. Lusedra, an aqueous solution, is an intravenous sedative-hypnotic agent
Cmed has announced the opening of its second US office in Durham, North Carolina. The company said the new office is established to meet the needs of the
AstraZeneca has announced results of a PLATO sub-analysis in Acute Coronary Syndrome (ACS) patients, those with ST Segment Elevation Myocardial Infarction (STEMI). The sub-analysis showed that, compared to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.